



ANDA 207344

**ANDA APPROVAL**

Fresenius Kabi USA, LLC  
Three Corporate Drive  
Lake Zurich, IL 60047  
Attention: Dimitar Ivanov  
Senior Regulatory Specialist

Dear Sir:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on June 16, 2014, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Micafungin for Injection, 50 mg/vial and 100 mg/vial Single-Dose Vials.

Reference is also made to the complete response letter issued by this office on January 11, 2019, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the ANDA is **approved**, effective on the date of this letter. The Office of Bioequivalence has determined your Micafungin for Injection, 50 mg/vial and 100 mg/vial Single-Dose Vials, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Mycamine for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. (Astellas).

The RLD upon which you have based your ANDA, Astellas's Mycamine for Injection, 50 mg/vial and 100 mg/vial, is subject to a period of patent protection. The following patent and expiration date is currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
6,774,104 (the '104 patent)	January 8, 2021

Your ANDA contains a paragraph IV certification to the '104 patent under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Micafungin for Injection, 50 mg/vial and 100 mg/vial Single-Dose Vials, under this ANDA. You have notified the Agency that Fresenius Kabi USA, LLC (Fresenius) complied with the requirements of section 505(j)(2)(B) of the FD&C Act and that litigation was initiated within the statutory 45-day period against Fresenius for infringement of the '104 patent in the United States District Court for the District of Delaware [Astellas Pharma Inc., Astellas US LLC, and Astellas Pharma US, Inc. v. Fresenius Kabi USA, LLC, Civil Action No. 15-00080]. You have also notified the Agency that this case was dismissed.

With respect to 180-day generic drug exclusivity, we note that Fresenius was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Micafungin for Injection, 50 mg/vial and 100 mg/vial Single-Dose Vials. Therefore, with this approval, Fresenius is eligible for 180 days of generic drug exclusivity for Micafungin for Injection, 50 mg/vial and 100 mg/vial Single-Dose Vials. It is noted that this ANDA was not tentatively approved within 30-month period described in section 505(j)(5)(D)(i)(IV) of the FD&C Act. Nevertheless, the Agency has determined that Fresenius has not, at this time, forfeited its eligibility for 180-day generic drug exclusivity.<sup>1</sup> This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

### **REPORTING REQUIREMENTS**

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at: <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at: <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see: <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **ANNUAL FACILITY FEES**

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions<sup>2</sup> with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1<sup>st</sup> of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts.

All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at: <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

*{See appended electronic signature page}*

For Vincent Sansone, PharmD  
Deputy Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research

---

<sup>1</sup> ANDA 207344 was received on June 16, 2014. This ANDA was never tentatively approved and therefore was not granted tentative approval within the 30-month period described in section 505(j)(5)(D)(i)(IV) of the FD&C Act. Nevertheless, the Agency has determined that the failure to obtain tentative approval within the 30-month period was caused by a change in or a review of the requirements for approval of the application imposed after the date on which the application was filed.

<sup>2</sup> Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).



Catherine  
Poole

Digitally signed by Catherine Poole

Date: 5/17/2019 08:33:56AM

GUID: 5407887a000a1c0c26055eafb8e3258a